2.38
price down icon1.24%   -0.03
pre-market  Vorhandelsmarkt:  2.38  
loading
Schlusskurs vom Vortag:
$2.41
Offen:
$2.3708
24-Stunden-Volumen:
199.43K
Relative Volume:
0.05
Marktkapitalisierung:
$133.07M
Einnahmen:
$76.19M
Nettoeinkommen (Verlust:
$-1.61M
KGV:
238.00
EPS:
0.01
Netto-Cashflow:
$28.98M
1W Leistung:
-3.64%
1M Leistung:
-18.77%
6M Leistung:
+173.31%
1J Leistung:
+72.46%
1-Tages-Spanne:
Value
$2.37
$2.41
1-Wochen-Bereich:
Value
$2.30
$2.531
52-Wochen-Spanne:
Value
$0.5052
$3.22

Spero Therapeutics Inc Stock (SPRO) Company Profile

Name
Firmenname
Spero Therapeutics Inc
Name
Telefon
857-242-1600
Name
Adresse
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Name
Mitarbeiter
32
Name
Twitter
@spero_tx
Name
Nächster Verdiensttermin
2025-03-19
Name
Neueste SEC-Einreichungen
Name
SPRO's Discussions on Twitter

Vergleichen Sie SPRO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SPRO
Spero Therapeutics Inc
2.38 134.74M 76.19M -1.61M 28.98M 0.01
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-20 Herabstufung Evercore ISI Outperform → In-line
2022-09-23 Hochstufung Evercore ISI In-line → Outperform
2021-10-01 Herabstufung Oppenheimer Outperform → Perform
2021-01-22 Bestätigt H.C. Wainwright Buy
2020-12-16 Eingeleitet Berenberg Buy
2020-09-29 Eingeleitet Evercore ISI Outperform
2019-11-05 Bestätigt H.C. Wainwright Buy
2019-09-09 Eingeleitet Janney Buy
2018-02-09 Eingeleitet Cantor Fitzgerald Overweight
2017-11-27 Eingeleitet BofA/Merrill Neutral
2017-11-27 Eingeleitet Oppenheimer Outperform
2017-11-27 Eingeleitet Stifel Buy
Alle ansehen

Spero Therapeutics Inc Aktie (SPRO) Neueste Nachrichten

pulisher
Jul 23, 2025

What drives Spero Therapeutics Inc. stock priceConsistently outstanding ROI - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Spero Therapeutics Inc. stockOutstanding capital appreciation - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Is Spero Therapeutics Inc. a good long term investmentFree Bull & Bear Market Updates - Autocar Professional

Jul 22, 2025
pulisher
Jul 19, 2025

Spero Therapeutics Inc. Stock Analysis and ForecastPowerful growth strategies - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

Will Spero Therapeutics Inc. stock benefit from AI tech trendsTrend Based Entry Alerts - Newser

Jul 18, 2025
pulisher
Jul 18, 2025

When is the best time to buy Spero Therapeutics Inc. stockFree Real-Time Trading Opportunities - Newser

Jul 18, 2025
pulisher
Jul 16, 2025

Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price - simplywall.st

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Spero Therapeutics Inc. stock price move sharplyMarket Timing Advice - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Spero Therapeutics Inc. stock attracts strong analyst attentionTop Momentum Stock Pick - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Spero Therapeutics Inc. stock performs during market volatilityBreakout Level Watch - Newser

Jul 15, 2025
pulisher
Jul 01, 2025

Spero Therapeutics (NASDAQ:SPRO) Stock Passes Above Fifty Day Moving Average – What’s Next? - Defense World

Jul 01, 2025
pulisher
Jun 28, 2025

While institutions own 20% of Spero Therapeutics, Inc. (NASDAQ:SPRO), retail investors are its largest shareholders with 54% ownership - Yahoo

Jun 28, 2025
pulisher
Jun 25, 2025

Is Spero Therapeutics, Inc. overvalued or undervalued? - MarketsMojo

Jun 25, 2025
pulisher
Jun 17, 2025

Complicated Urinary Tract Infection Pipeline Appears Robust With 12+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

Jun 17, 2025
pulisher
Jun 12, 2025

SPRO’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com

Jun 12, 2025
pulisher
Jun 11, 2025

Spero TherapeuticsAdditional Upside Potential Following Positive Phase 3 Results (SPRO) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 11, 2025

Squarepoint Ops LLC Buys Shares of 55,051 Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World

Jun 11, 2025
pulisher
Jun 09, 2025

Spero Therapeutics COO Timothy Keutzer sells shares for $44,097 - MSN

Jun 09, 2025
pulisher
Jun 09, 2025

Jane Street Group LLC Takes Position in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World

Jun 09, 2025
pulisher
Jun 06, 2025

Spero Therapeutics Inc (SPRO) Is A Good Stock To Invest In - Stocksregister

Jun 06, 2025
pulisher
Jun 06, 2025

Spero Therapeutics, Inc. (NASDAQ:SPRO) Stake Boosted by Mackenzie Financial Corp - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled - MSN

Jun 06, 2025
pulisher
Jun 04, 2025

Northern Trust Corp Sells 25,050 Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World

Jun 04, 2025
pulisher
May 31, 2025

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week - Insider Monkey

May 31, 2025
pulisher
May 31, 2025

Spero Therapeutics stock hits 52-week high at $2.53 By Investing.com - Investing.com South Africa

May 31, 2025
pulisher
May 31, 2025

Complicated Urinary Tract Infection Oral Antibiotic Approaches Approval - Vax-Before-Travel

May 31, 2025
pulisher
May 30, 2025

Spero Therapeutics stock hits 52-week high at $2.53 - Investing.com India

May 30, 2025
pulisher
May 30, 2025

Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone - MSN

May 30, 2025
pulisher
May 30, 2025

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal - MSN

May 30, 2025
pulisher
May 29, 2025

Spero Therapeutics Stock (SPRO) Rockets 225% on Clinical Trial Data - The Globe and Mail

May 29, 2025
pulisher
May 29, 2025

Spero Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance

May 29, 2025
pulisher
May 29, 2025

Spero Therapeutics rockets on positive Phase III study for tebipenem HBr - The Pharma Letter

May 29, 2025

Finanzdaten der Spero Therapeutics Inc-Aktie (SPRO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Kapitalisierung:     |  Volumen (24h):